A citation-based method for searching scientific literature

Josep Tabernero, Paulo M Hoff, Lin Shen, Atsushi Ohtsu, Manish A Shah, Karen Cheng, Chunyan Song, Haiyan Wu, Jennifer Eng-Wong, Katherine Kim, Yoon-Koo Kang. Lancet Oncol 2018
Times Cited: 204

E C Smyth, M Verheij, W Allum, D Cunningham, A Cervantes, D Arnold. Ann Oncol 2016
Times Cited: 835

List of shared articles

Times cited

Current status and future perspectives in HER2 positive advanced gastric cancer.
G Roviello, M Catalano, L F Iannone, L Marano, M Brugia, G Rossi, G Aprile, L Antonuzzo. Clin Transl Oncol 2022

Chemorefractory Gastric Cancer: The Evolving Terrain of Third-Line Therapy and Beyond.
Maria Alsina, Josep Tabernero, Marc Diez. Cancers (Basel) 2022

Evolution of predictive and prognostic biomarkers in the treatment of advanced gastric cancer.
Nicole M Myer, Kohei Shitara, Hyun C Chung, Florian Lordick, Ronan J Kelly, Zsolt Szabo, Z Alexander Cao, Stephen Leong, David H Ilson, Wilko Weichert. J Cancer Res Clin Oncol 2022

The HIF-1α as a Potent Inducer of the Hallmarks in Gastric Cancer.
Cemre Ucaryilmaz Metin, Gulnihal Ozcan. Cancers (Basel) 2022

Resistance mechanisms to HER2-targeted therapy in gastroesophageal adenocarcinoma: A systematic review.
Dionne Blangé, Charlotte I Stroes, Sarah Derks, Maarten F Bijlsma, Hanneke W M van Laarhoven. Cancer Treat Rev 2022

HERIZON-GEA-01: Zanidatamab + chemo ± tislelizumab for 1L treatment of HER2-positive gastroesophageal adenocarcinoma.
Josep Tabernero, Lin Shen, Elena Elimova, Geoffrey Ku, Tianshu Liu, Kohei Shitara, Xiao Lin, Lisa Boyken, Huiyan Li, Jonathan Grim,[...]. Future Oncol 2022

European-Australasian consensus on the management of advanced gastric and gastro-oesophageal junction cancer: current practice and new directions.
Nick Pavlakis, Gary Tincknell, Lisi Elizabeth Lim, Kei Muro, Radka Obermannova, Sylvie Lorenzen, Yu Jo Chua, Chris Jackson, Christos Stelios Karapetis, Timothy Price,[...]. Ther Adv Med Oncol 2022

First-line pembrolizumab/placebo plus trastuzumab and chemotherapy in HER2-positive advanced gastric cancer: KEYNOTE-811.
Hyun Cheol Chung, Yung-Jue Bang, Charles S Fuchs, Shu-Kui Qin, Taroh Satoh, Kohei Shitara, Josep Tabernero, Eric Van Cutsem, Maria Alsina, Zhu Alexander Cao,[...]. Future Oncol 2021

Changes in the therapeutic landscape of oesophago-gastric cancers.
Nina Fokter Dovnik, Elizabeth C Smyth. Curr Opin Oncol 2021

Human epidermal growth factor receptor 2 (HER2) in advanced gastric cancer: where do we stand?
Giandomenico Roviello, Giuseppe Aprile, Alberto D'Angelo, Luigi Francesco Iannone, Franco Roviello, Karol Polom, Enrico Mini, Martina Catalano. Gastric Cancer 2021

Synergistic antitumor effect of the anti-ErbB2 antibodies trastuzumab and H2-18 on trastuzumab-resistant gastric cancer cells.
Chao Wang, Lingfei Wang, Beibei Liang, Bo Zhou, Yu Sun, Yanchun Meng, Jian Dong, Lin Chen, Bohua Li. Oncol Lett 2021

Trastuzumab deruxtecan for the treatment of HER2-positive gastric cancer.
Saori Mishima, Kohei Shitara. Expert Opin Biol Ther 2021

Bone Metastases from Gastric Cancer: What We Know and How to Deal with Them.
Angelica Petrillo, Emilio Francesco Giunta, Annalisa Pappalardo, Davide Bosso, Laura Attademo, Cinzia Cardalesi, Anna Diana, Antonietta Fabbrocini, Teresa Fabozzi, Pasqualina Giordano,[...]. J Clin Med 2021

Hopes and failures in front-line advanced HER2-positive gastric cancer therapy.
Fanming Kong, Yang Yao, Renfen Deng, Xiaojiang Li, Yingjie Jia. Anticancer Drugs 2021

Targeted and immunotherapy in the era of personalised gastric cancer treatment.
Silvia Catanese, Florian Lordick. Best Pract Res Clin Gastroenterol 2021

A Phase II Study of the Combination of Oxaliplatin, Capecitabine, and Trastuzumab and Chemoradiotherapy in the Adjuvant Setting in Operated Patients With HER2-positive Gastric or Gastroesophageal Junction Cancer (TOXAG Study): A Turkish Oncology Group Study.
Huseyin Abali, Suayib Yalcin, Huseyin C Onal, Faysal Dane, Berna Oksuzoglu, Nuriye Ozdemir, Huseyin Mertsoylu, Mehmet Artac, Celaletdin Camci, Bulent Karabulut,[...]. Am J Clin Oncol 2021